GMED logo

GMED
Globus Medical Inc

1,578
Mkt Cap
$11.19B
Volume
1.97M
52W High
$101.40
52W Low
$51.79
PE Ratio
19.07
GMED Fundamentals
Price
$81.88
Prev Close
$82.45
Open
$82.61
50D MA
$87.20
Beta
0.97
Avg. Volume
1.01M
EPS (Annual)
$3.92
P/B
2.35
Rev/Employee
$489,821.83
$11,528.56
Loading...
Loading...
News
all
press releases
Here's Why You Should Hold Avantor Stock in Your Portfolio for Now
AVTR's product breadth, digital upgrades and new pharma wins support growth, though VWR Distribution & Services remains a challenge.
Zacks
News Placeholder
More News
News Placeholder
Teladoc Health Broadens Virtual Care Reach Through Walmart Platform
TDOC teams with Walmart to offer virtual urgent care, dermatology and nutrition services, expanding affordable telehealth access nationwide.
Zacks
News Placeholder
HealthEquity Stock Gains as Q1 Earnings Top Estimates, Revenues Up Y/Y
HQY tops Q1 FY27 EPS and revenue estimates as HSA accounts and assets climb, and guidance for FY27 revenues and adjusted EPS rises.
Zacks
News Placeholder
GMED's Robotics Leasing Shift Could Build Recurring Revenue
Globus Medical is shifting robotics deals to leases and rentals, aiming to expand its installed base and build recurring revenue streams.
Zacks
News Placeholder
Reasons to Retain TransMedics Stock in Your Portfolio for Now
TMDX is advancing its OCS platform and transplant ecosystem, but margin pressure from expansion investments remains a key concern.
Zacks
News Placeholder
Natera to Launch Enhanced Panorama NIPT for Low Fetal Fractions
NTRA upgrades Panorama NIPT with SNP-informed deep sequencing, validated for low fetal fraction to cut no-calls and boost reliable prenatal results.
Zacks
News Placeholder
Is it a Prudent Move to Retain ALC Stock in Your Portfolio Now?
Alcon's Surgical and Vision Care units returned to 6% growth in Q1 2026, but tariffs, macro pressure and fierce competition still loom.
Zacks
News Placeholder
Is This the Right Time to Keep HSIC Stock in Your Portfolio?
Henry Schein is backed by a dental and medical distribution scale, digital dentistry push and acquisitions, but debt and macro headwinds weigh on its outlook.
Zacks
News Placeholder
Myriad Genetics' Upcoming Prolaris + AI Test Debut May Lift Its Stock
MYGN plans to launch its Prolaris + AI Test this month, combining biomarker data and AI pathology to personalize prostate cancer surveillance.
Zacks
News Placeholder
GMED Growth Drivers After NuVasive and What Q1 Signals
Globus Medical's Q1 showed margin gains, strong spine and trauma growth, and rising robotics adoption as NuVasive synergies support 2026 targets.
Zacks
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available